Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03677440
Other study ID # IRB-300000111
Secondary ID 1R01HD091155-01A
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 5, 2019
Est. completion date August 30, 2024

Study information

Verified date March 2024
Source Kessler Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cognitive impairment is highly prevalent, poorly-managed, and disabling in persons with MS and exercise training might represent a promising approach to manage this symptom of the disease. The proposed study aims to examine the effects of 3-months of supervised, progressive (both intensity and duration) treadmill walking exercise training (designed based on pilot work and American College of Sports Medicine guidelines) compared with an active control condition (i.e., stretching-and-toning activities) on cognitive processing speed and functional MRI outcomes in 88 cognitively-impaired persons with MS. This study is critical for providing evidence supporting treadmill walking exercise training as a behavioral approach for managing slowed cognitive processing speed (i.e., the most common MS-related cognitive impairment) and improving brain health in persons with MS.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 43
Est. completion date August 30, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility All participants will: - Be between the ages of 18-65 - Have a clinically definite MS diagnosis based on established criteria - Be fully-ambulatory based on Expanded Disability Status Scale (EDSS) scores between 0-4.0 - Demonstrate slowed CPS based on initial SDMT scores at least 1 SD below the regression-based normative score for healthy controls (i.e., 16th percentile) - Be relapse-free and will not have acutely taken corticosteroids for at least 30 days (i.e., relative neurologic stability) - Not have a history of major depressive disorder, schizophrenia, bipolar disorder I or II, or substance-abuse disorders. - Not be taking medications that can affect cognition (e.g., antipsychotics, benzodiazepines). - Be right-handed - Have corrected vision better than 20/80 - Not have known/diagnosed cardiovascular, metabolic, or renal disease. Individuals with known/diagnosed cardiovascular, metabolic, or renal disease who are asymptomatic will be included only with a physician's approval. - Demonstrate scores on the Mini-Mental State Examination (MMSE) of 21 or higher (no decisional impairment) - Be on a stable disease-modifying therapy regimen (i.e., at least 6 months prior to study enrollment). - Have a low risk for contraindications for MRI based on not having metal (e.g., non-MRI compatible aneurysm clips, metal shards in the body or eyes, or recently placed surgical hardware) or electronic devices (e.g., pacemaker, cochlear implant) within the body. - Not be pregnant - Not be engaging in = 150 min of moderate-to-vigorous physical activity (i.e., not meeting public health guidelines for physical activity) per week - Not be actively engaging in cognitive rehabilitation, or participating in regular brain fitness activities - Demonstrate systolic blood pressure values of < 200 mmHg or diastolic blood pressure values < 110 mmHg at rest

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Treadmill Walking Exercise Training
12-weeks of supervised, progressive treadmill walking exercise training
Stretching-and-Toning Exercise Training
12-weeks of supervised, progressive stretching-and-toning exercise training

Locations

Country Name City State
United States Kessler Foundation West Orange New Jersey

Sponsors (3)

Lead Sponsor Collaborator
Kessler Foundation Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cognitive Processing Speed Raw (Total) Score from the Symbol Digit Modalities Test (0-110; higher scores indicate faster cognitive processing speed) Every 12 weeks
Primary Thalamocortical Resting-State Functional Connectivity Region 1 Functional connectivity between the thalamus and right medial frontal gyrus based on fMRI Every 12 weeks
Primary Thalamocortical Resting State Functional Connectivity Region 2 Resting-state functional connectivity between the thalamus and anterior cingulate cortex based on fMRI Every 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4